Biotech Values

[DewDiligence]

BMY/BLUE/BMYRT—bb2121 PDUFA is 3/27/21 (with priority review):

https://www.businesswire.com/news/home/20200922005376/en/U.S.-Food-and-Drug-Administration-FDA-Accepts-for-Priority-Review-Bristol-Myers-Squibb-and-bluebird-bio-Application-for-Anti-BCMA-CAR-T-Cell-Therapy-Idecabtagene-Vicleucel-Ide-cel-bb2121

The PDUFA date is a mere four days before the FDA-approval deadline to trigger a $9/sh payoff for holders of BMYRT (#msg-145844551).